Pfizer
AstraZeneca’s second quarter beats estimates
July 31, 2014Research and Development, Sales and Marketing AstraZeneca, Nexium, Pfizer
AstraZeneca posted a set of healthy financial results today as key platforms performed well for the company. Revenue in the …
AstraZeneca secures respiratory drugs from Almirall
July 30, 2014Research and Development, Sales and Marketing Almirall, AstraZeneca, Pfizer, Symbicort, lung drugs
AstraZeneca has paid $875 million to take control of Alimirall’s respiratory drug portfolio that includes treatments for bronchitis and emphysema. …
Pfizer revenue drops, but new cancer drugs shine
July 29, 2014Research and Development, Sales and Marketing Cancer, Inlyta. axitinib, Lipitor, Lyrica, Pfizer, Q2, Sutent, viagra
Pfizer saw a 2% drop in sales for the second quarter but has pointed to the stellar growth of its …
Pharma firms give researchers access
July 22, 2014Research and Development, Sales and Marketing AstraZeneca, GlaxoSmithKline, Janssen R&D, MRC, Pfizer, Takeda, UCB, lilly, research, virtual library
UK researchers are to gain access to compounds from seven pharma companies in a partnership with the Medical Research Council …
Pfizer to pay $360m for InnoPharma
July 18, 2014Sales and Marketing Pfizer, injectables, innopharma
Pfizer is to pay as much as $360 million for private pharma development company InnoPharma in a financial arrangement comprising …
Bayer hires litigation head from Pfizer
July 17, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bayer, Malini Moorthy, Pfizer
Bayer Healthcare has appointed Malini Moorthy to head up its litigation department in the US. Moorthy joins the German firm from …
Targacept admits failure in Alzheimer’s trial
July 15, 2014Research and Development, Sales and Marketing Alzheimer's, Aricept, Pfizer, TC-173, Targacept
Targacept is dropping a once promising Alzheimer’s drug from further clinical trials after it failed to beat Pfizer’s Aricept (donepezil) …
Alynlam secures fomer Pfizer head
July 7, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Pfizer, alynlam, amy schulman
US biotech firm Alynlam has elected Pfizer’s former executive VP and general counsel Amy Schulman to its board of directors. …
Majority of consumed Viagra fake say researchers
July 3, 2014Manufacturing and Production, Sales and Marketing BMJ, ED, Pfizer, Sildenafil, counterfeit, erectile dysfunction, viagra
At least two-thirds of Pfizer’s erectile dysfunction drug Viagra used in the Netherlands may be illegal, researchers are warning. In …
Reuters chief executive joins Pfizer board
July 2, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Pfizer, james smith, reuters
Pfizer has appointed the chief executive of information and media giant Thomson Reuters to its board of directors. James Smith …
Drug prices defy gravity – until patent expiry
June 23, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing John LaMattina, LaMattina, Pfizer, drug, pharma, pricing, research
How drugs are priced is a hot topic these days, and a new Bloomberg article will cause it to heat-up …
AbbVie moves in on Shire with $46 billion bid
June 20, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AbbVie, Abbott, AstraZeneca, Pfizer, Shire, merger
AbbVie is looking to acquire Ireland-based speciality biopharma firm Shire in a deal that could shore up the US company’s …
Genome-driven lung cancer trial launches
June 18, 2014Research and Development, Sales and Marketing AstraZeneca, Cancer, Genentech, MedImmune, Pfizer, genome, lung cancer
Amgen, Genentech, Pfizer, AstraZeneca and MedImmune – AstraZeneca’s global biologics R&D arm – have each put investigative treatments into a …
ABPI president: NICE needs political reform
June 17, 2014Business Services, Medical Communications, Research and Development ABPI, NHS, NICE, Pfizer, QALY, emms, jonathan, vba
NICE needs to be reformed with its QALY formula heavily revised if it is to meet the challenges of 21st …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
